证券代码：000925 证券简称：众合科技 公告编号：临 2025—072 浙江众合科技股份有限公司 关于"杭州市城市轨道交通 15 号线一期工程自动售检票系 统（AFC）及票务系统线网平台设备采购项目"中标的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 1 / 2 2025 年 10 月 20 日 ， 机 电 产 品 招 标 投 标 电 子 交 易 平 台 （https://www.chinabidding.com/bidDetail/262145000-BidResult.html）发 布《杭州市城市轨道交通 15 号线一期工程自动售检票系统（AFC）及票务系统线 网平台设备采购项目中标结果公告》，确认浙江众合科技股份有限公司（以下简 称"公司"）全资子公司浙江众合轨道交通智能系统有限公司为"杭州市城市轨 道交通 15 号线一期工程自动售检票系统（AFC）及票务系统线网平台设备采购项 目"的中标人。 一、项目基本情况 项目名称：杭州市城市轨道交通 15 号线一期工程自动售检票系统（AFC）及 票务系统线网平台设备采购项目 招标人：杭州市地铁集团有限责 ...

Core Insights - The medical device CDMO sector in China is experiencing growth driven by policy support and increasing demand, with expectations to replicate the successful trajectory of the pharmaceutical CXO model over the next five years [1][6]. Policy Support - The China Federation of Logistics and Purchasing reported that the market size of the medical device industry is projected to reach 1.2 trillion yuan by 2024 [1]. - The implementation of the MAH system allows R&D companies to outsource production, providing significant policy support for the industry [2]. - The demand for innovation and cost control due to centralized procurement and medical insurance payment reforms is pushing companies to focus on medical device CDMO [2]. Industry Landscape - The global medical device CDMO market is expected to grow at a compound annual growth rate (CAGR) of 16.3% from 2020 to 2025, significantly outpacing the overall medical device industry growth [2]. - Domestic companies are rapidly entering the CDMO space, with firms like Meihao Medical providing comprehensive services from product development to mass delivery [3]. - High-end medical device sectors, such as surgical robots, show a particularly strong demand for CDMO platforms, which can facilitate faster product development and compliance [4]. Company Strategies - Companies are increasingly collaborating with CDMO platforms to enhance their product development capabilities and reduce time to market [4]. - Non-medical device companies, such as Huoyi Technology, are also entering the CDMO space, leveraging technology transfer and attracting global talent [4]. - The industry is characterized by a fragmented "specialized and precise" model, with a focus on specialized processes and engineering experience [5]. Future Outlook - The medical device CDMO sector is at a critical transition phase, moving from niche markets to broader product lines and upgrading from traditional OEM to full-service CDMO offerings [6]. - Key growth areas include high-value consumables, precision processing, and automated sterilization platforms [6]. - The industry is expected to face challenges such as talent shortages and insufficient intellectual property protection, necessitating coordinated efforts for talent development and regulatory compliance [7]. Development Pathways - The industry is likely to see the emergence of 1-2 leading companies capable of providing integrated services from R&D to mass production within the next 3-5 years [8]. - Companies are encouraged to focus on single market segments initially, ensuring quality and delivery efficiency before expanding into adjacent categories through mergers and acquisitions [8].

Core Insights - The medical device CDMO sector in China is experiencing significant growth driven by policy support and surging demand, with expectations to replicate the successful trajectory of the pharmaceutical CXO model over the next five years [1][7]. Policy Support - The Chinese medical device market is projected to reach 1.2 trillion yuan by 2024, indicating robust growth potential [2]. - Global leaders in the medical device industry have long outsourced production to specialized CDMO providers to enhance R&D efficiency and reduce time-to-market for new products [2]. - The implementation of the MAH system allows R&D companies to outsource production, providing a significant policy boost to the industry [3]. Industry Demand - There is a growing demand for CDMO services in high-end medical equipment sectors, particularly in surgical robotics, where innovative companies require robust support for product commercialization [5]. - The medical device CDMO market is expected to grow rapidly, with a projected annual compound growth rate of 16.3% from 2020 to 2025, significantly outpacing the overall medical device industry growth [2]. Company Developments - Companies like Meihua Medical are actively expanding their CDMO capabilities, offering comprehensive services from product development to mass delivery across various medical device segments [4]. - The establishment of high-end medical device CDMO platforms, such as Shuimu Dongfang, is facilitating the acceleration of product development and market entry for innovative projects [5]. Market Trends - The Chinese medical device CDMO sector is transitioning from a focus on specific segments like IVD to a broader range of product lines and full-service capabilities [7]. - The industry is characterized by a fragmented landscape with a focus on specialized, high-quality services rather than large-scale operations [6]. Future Outlook - The next 3-5 years are critical for the industry, with expectations for the emergence of 1-2 leading companies capable of providing integrated services from R&D to mass production [9]. - Key growth areas include high-value consumables, automated filling and sterilization platforms, and the development of accelerators for prototype registration and small batch production [7].

Group 1 - Company announced a share buyback program, repurchasing approximately 5.8 million shares, which represents 0.86% of the total share capital [1] - The buyback was conducted through a special securities account via centralized bidding, with a total transaction amount of approximately 44.62 million yuan [1] - The highest transaction price was 8.38 yuan per share, while the lowest was 7.4 yuan per share, in compliance with relevant laws and regulations [1] Group 2 - The current market capitalization of the company is 5.4 billion yuan [2]

格隆汇10月9日丨众合科技(000925.SZ)公布，截至2025年9月30日，公司通过回购专用证券账户，以集 中竞价方式累计回购了5,802,883股，占公司目前总股本的0.86%，其中最高成交价为8.38元/股，最低成 交价为7.40元/股，合计成交总金额为44,619,397.91元（不含印花税、交易佣金等交易费用），本次回购 符合相关法律法规的要求，符合公司既定的回购方案。 ...

格隆汇10月9日丨众合科技(000925.SZ)公布，截至2025年9月30日，公司通过回购专用证券账户，以集 中竞价方式累计回购了5,802,883股，占公司目前总股本的0.86%，其中最高成交价为8.38元/股，最低成 交价为7.40元/股，合计成交总金额为44,619,397.91元（不含印花税、交易佣金等交易费用），本次回购 符合相关法律法规的要求，符合公司既定的回购方案。 ...

证券代码：000925 证券简称：众合科技 公告编号：临 2025-070 二、其他说明 （一）公司未在下列期间内回购股份： 1、自可能对公司证券及其衍生品种交易价格产生重大影响的重大事项发生 之日或者在决策过程中，至依法披露之日内； 2、中国证监会和深圳证券交易所规定的其他情形。 （二）公司以集中竞价交易方式回购股份符合下列要求： 1、委托价格不得为公司股票当日交易涨幅限制的价格； 浙江众合科技股份有限公司 关于股份回购进展情况的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 浙江众合科技股份有限公司（以下简称"公司"）于 2025 年 1 月 20 日召开 的第九届董事会第八次会议审议通过了《关于回购部分社会公众股份方案暨取得 股票回购专项贷款的议案》，同意公司使用自有资金及股票回购专项贷款资金通 过集中竞价交易方式回购部分股份用于股权激励或员工持股计划，回购总金额不 低于人民币 4,250 万元（含）且不超过人民币 8,500 万元（含），回购价格不超 过人民币 12.46 元/股（含），实施期限为自董事会审议通过本次回购方案之日 起 12 个月内。 ...

证券代码：000925 证券简称：众合科技 公告编号：临 2025-071 浙江众合科技股份有限公司 关于 2020 年员工持股计划存续期即将届满的提示性公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 浙江众合科技股份有限公司（以下简称"众合科技""公司"）于 2020 年 3 月 25 日召开的第七届董事会第十三次会议及 2020 年 4 月 13 日召开的 2020 年 第一次临时股东会审议通过了《浙江众合科技股份有限公司 2020 年员工持股计 划（草案）》及其摘要，详见 2020 年 3 月 27 日刊登于《中国证券报》《证券时 报》《证券日报》和巨潮资讯网（http://www.cninfo.com.cn）的相关公告。 公司 2020 年员工持股计划存续期将于 2026 年 4 月 10 日届满。目前，管理 委员会已制订了本期员工持股计划减持方案。存续期届满前，根据市场情况有序 实施减持，并遵守《深圳证券交易所上市公司自律监管指引第 1 号——主板上市 公司规范运作》关于员工持股计划减持窗口期的规定。 根据《关于上市公司实施员工持股计划试点的指导 ...

Group 1 - The company announced the expected total amount of daily related transactions for 2025 is estimated to be 36,207,000 RMB [2][9] - The company plans to engage in daily related transactions with the newly associated party, Zhejiang Wangxin Intelligent Technology Co., Ltd., amounting to 2,618,970 RMB for 2025 [3][9] - The board of directors approved the proposal for the expected daily related transactions, which do not require shareholder approval [3][10] Group 2 - The company transferred 53.8462% of its stake in Wangxin Intelligent to Beijing Yuanzitop Technology Co., Ltd. and Hangzhou Junyi Information Technology Service Partnership, retaining 33.1506% of the stake [3][19] - The transaction price for the stake transfer was approximately 10,986,177 RMB, based on an asset evaluation report [17][31] - The company will not consolidate Wangxin Intelligent into its financial statements post-transaction, thus changing its consolidation scope [19][42] Group 3 - The company has signed contracts for raw material procurement with Wangxin Intelligent amounting to 73,623,300 RMB, with 50,343,000 RMB yet to be fulfilled [8][40] - The company emphasizes that all transactions will be conducted based on market principles and will not harm the interests of shareholders, especially minority shareholders [9][10] - The purpose of the transaction is to optimize resource allocation and enhance operational efficiency, benefiting both the company and Wangxin Intelligent [41][42]

本次交易完成后，由于众合科技的高管在网新智能任职，网新智能将被动成为众合科技的关联人。公司 与网新智能仍存在未履行完成的原材料采购合同：截至公告日，众合科技及子公司向网新智能采购原材 料已签订合同金额7,362.33万元，尚有5,034.30万元未履行完成。2025年度众合科技及子公司与网新智能 的关联交易预计2,618.97万元。 格隆汇9月29日丨众合科技(000925.SZ)公布，本次交易为众合科技全资子公司众合轨道向北京元子和杭 州君毅合计转让网新智能53.8462%的股权（对应注册资本13,603,166元），作价10,986,177元，定价依 据为天源资产评估有限公司出具的《资产评估报告》。本次交易完成后，众合轨道仍持有网新智能 33.1506%的股权，但网新智能不再纳入众合科技合并报表范围。 ...